Genevatropin HGH is a synthetic form of human growth hormone (HGH) that is used for treating growth hormone deficiency in children and adults. It is sold in the form of vials that contain a sterile, non-pyrogenic, white lyophilized powder that should be reconstituted before use. The product is manufactured by Genevatropin Biotech, Co., Ltd.

Indication:
Genevatropin HGH is indicated for treating growth hormone deficiency, Turner syndrome, and chronic renal insufficiency. It is also used off-label for improving body composition, increasing muscle mass, and reducing fat mass.

Mechanism of Action:
Genevatropin HGH stimulates the production of insulin-like growth factor-1 (IGF-1) in the liver, which promotes growth and cell reproduction. It also promotes the utilization of fats for energy sources and the production of glucose in the liver.

Administration:
Genevatropin HGH is administered through a subcutaneous injection. The injection site should be varied to avoid the formation of lipodystrophies. The product should be reconstituted with bacteriostatic water before injection.

Dosage:
The dosage of Genevatropin HGH varies depending on the patient’s age, weight, and condition. The recommended dose is 0.2-0.3 mg/kg/week for children. The maximum dose should not exceed 0.5 mg/kg/week.

Efficacy:
Genevatropin HGH has been shown to be effective in increasing linear growth and lean muscle mass in children and improving body composition in adults. The efficacy of the drug may vary depending on the patient’s response to the treatment.

Side Effects:
The common side effects of Genevatropin HGH include injection site reactions, swollen joints, headache, and muscle pain. The less common side effects include hypertension, hyperglycemia, and increased risk of developing malignancies. The long-term use of the drug may increase the risk of developing diabetes, especially in patients with a family history of diabetes.

Precautions:
Genevatropin HGH should not be used in patients with acute critical illnesses or respiratory failure. Patients should be monitored carefully for the development of diabetes or other metabolic disorders. The product should only be used under the supervision of a qualified healthcare provider. The medication should be stored at room temperature, and the reconstituted solution should be used within a specified period.